Popular search terms:
Search Results Label
48 results found-
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
https://www.seqirus.us/expertise/influenza/pandemic-response-solutions -
Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
https://www.seqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity -
Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.seqirus.us/expertise -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news -
Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine
https://www.seqirus.us/news/seqirus-presents-new-late-breaking-data-at-eswi-2020 -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/seqirus-presents-first-of-its-kind-study-on-cell-based-quadrivalent-influenza-vaccine -
New Clinical Data Reinforces the Ability of MF59 Adjuvanted Seasonal and Pandemic Influenza Vaccines
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
https://www.seqirus.us/news/new-clinical-data-reinforces-the-ability-of-mf59-adjuvanted-seasonal-and-pandemic-influenza-vaccines -
Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020
https://www.seqirus.us/news/seqirus-presents-real-world-data-for-cell-based-quadrivalent -
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.
https://www.seqirus.us/news/seqirus-announces-major-advances-in-pandemic-preparedness